Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER) and progesterone receptor expression and human epidermal growth factor receptor 2 (ERBB2, formerly HER2) overexpression, is the most aggressive subtype, with more patients progressing to metastatic disease than any other breast cancer subtype. Here, ERBB2 is linked to triple-negative breast carcinoma.